Assemblies of tau and α-synuclein were shown to spread along interconnected neuronal networks suggesting broadly relevant therapeutic directions for Alzheimer’s and Parkinson’s disease. This requires a pre-clinical stage of development that has yet to be met. The scale of neurodegenerative disease burden in Europe calls for an unprecedented research effort that can only be achieved through collaboration between leading European laboratories and the pharmaceutical industry.
To meet this ambition the IMPRiND consortium will synergistically accelerate progress to map and target critical steps in the propagation, proteostatic response and protection against misfolded α-synuclein and tau.
Specifically we aim to
- (1) identify disease-relevant assemblies, imprint their biological properties in vitro and generate homogeneous populations to assay and interfere with their pathogenic effects;
- (2) develop and miniaturise assays to monitor secretion, uptake, clearance and oligomerisation using bimolecular fluorescence complementation of oligomeric species or transfer of untagged assemblies to fluorescently labelled fibril-naïve cells and measure markers of early proteotoxicity that are suitable for live imaging high content screens;
- (3) deliver robust validation assays for these molecular events in complex cellular systems with greater functional resemblance to the native milieu of the brain such as iPSC-based and organotypic cultures
- (4) standardise pathological readouts in animal models for in vivo validation of modifiers, correlate them with novel peripheral or in situ markers using microdialysis to accelerate the assessment of therapeutic interventions and relevance to humans, e.g. by transplantation of human iPSC neurons in animals;
- (5) assess toxicity and druggability of potential targets. IMPRiND will construct this entire pipeline to examine the prion-like properties of α-synuclein and tau and test their tractability against disease progression.
Abbvie Deutschland Gmbh & Co Kg
Deutsches Zentrum Fur Neurodegenerative Erkrankungen Ev
The Chancellor Masters And Scholarsof The University Of Cambridge
Novartis Pharma Ag
University Of Dundee
Idryma Iatroviologikon Ereunon Akademias Athinon
United Kingdom Research And Innovation
Universite De Bordeaux
H. Lundbeck As
Institut De Recherches Servier
Universitaetsmedizin Goettingen - Georg-August-Universitaet Goettingen - Stiftung Oeffentlichen Rechts
Centre National De La Recherche Scientifique Cnrs
Eli Lilly And Company Limited
Janssen Pharmaceutica Nv
Masters And Scholars Of The University Of Oxford